NASDAQ · ACRS
Healthcare · Medical - Diagnostics & Research
$3.60
Down-$0.23 (-6.01%)
Updated Oct 13, 2026, 1:17 PM
SID Score
5.6/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance · ACRS
1M range · 21 trading sessions · Daily adjusted prices
Prices through Oct 12, 2026
ACRS closed at $3.60 after 21 trading sessions, down 36.17% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 12, 2026 | $3.80 | $3.835 | $3.585 | $3.60 | 3.43M |
| Oct 9, 2026 | $3.76 | $3.94 | $3.64 | $3.83 | 5.06M |
| Oct 8, 2026 | $3.37 | $3.815 | $3.1818 | $3.79 | 8.74M |
| Oct 7, 2026 | $3.595 | $3.62 | $3.315 | $3.40 | 9M |
| Oct 6, 2026 | $4.22 | $4.24 | $3.65 | $3.70 | 3.53M |
| Oct 5, 2026 | $4.34 | $4.41 | $4.065 | $4.27 | 7.02M |
| Oct 2, 2026 | $4.44 | $4.52 | $4.205 | $4.39 | 6.21M |
| Oct 1, 2026 | $5.18 | $5.18 | $4.35 | $4.41 | 5.18M |
| Sep 30, 2026 | $5.30 | $5.395 | $5.21 | $5.26 | 2.26M |
| Sep 29, 2026 | $5.42 | $5.45 | $5.155 | $5.28 | 2.05M |
| Sep 28, 2026 | $5.07 | $5.465 | $5.02 | $5.43 | 2.43M |
| Sep 25, 2026 | $5.39 | $5.538 | $5.095 | $5.15 | 1.47M |
| Sep 24, 2026 | $5.24 | $5.44 | $5.145 | $5.38 | 2.49M |
| Sep 23, 2026 | $5.70 | $5.74 | $5.035 | $5.26 | 1.96M |
| Sep 22, 2026 | $5.63 | $5.765 | $5.50 | $5.72 | 2.88M |
| Sep 21, 2026 | $5.55 | $5.62 | $5.40 | $5.57 | 1.52M |
| Sep 18, 2026 | $5.41 | $5.535 | $5.36 | $5.50 | 4.69M |
| Sep 17, 2026 | $5.37 | $5.625 | $5.34 | $5.40 | 3.82M |
| Sep 16, 2026 | $5.54 | $5.56 | $4.975 | $5.32 | 5.77M |
| Sep 15, 2026 | $5.60 | $5.62 | $5.405 | $5.525 | 1.33M |
| Sep 14, 2026 | $5.29 | $5.715 | $5.29 | $5.64 | 5.84M |
The latest Smart Investors Daily articles mentioning ACRS.
Company
Market Activity
Research & News
ACRS research
Company profile and research snapshot.
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two reportable segments: therapeutics and contract research. The therapeutics segment is focused on identifying and developing inventive therapies to address unmet needs for immuno-inflammatory diseases, and the contract research segment is engaged in providing laboratory services. A majority of the company's revenue is derived from the therapeutics segment. The various drug candidates in its product pipeline are Zunsemetinib, which is an Oral MK2 Inhibitor; ATI-2138, an ITJ Inhibitor; Bosakitug, ATI-052, and Lepzacitinib.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Sep 1, 2026 | Canaccord Genuity | Buy | — |
| Jun 2, 2026 | LifeSci Capital | Outperform | — |
| May 5, 2026 | Piper Sandler | Overweight | — |
| May 5, 2026 | Guggenheim | Buy | — |
| Apr 29, 2026 | Wedbush | Outperform | — |
No generated briefing is available yet.
Benzinga · Mar 20, 2026
Aclaris Therapeutics, Inc. (NASDAQ:ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases, today announced that an ePoster on the results from
Benzinga · Mar 19, 2026
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Aclaris Therapeutics (NASDAQ:ACRS) with a Buy and maintains $16 price target.
Benzinga · Mar 18, 2026
Yahoo · Feb 26, 2026
Executives from Aclaris Therapeutics (NASDAQ:ACRS) outlined the company’s clinical-stage pipeline and upcoming catalysts during a presentation at Oppenheimer’s Annual Healthcare Conference, emphasizing programs in inflammatory and immunological diseases spanning monoclonal antibodies, a bispecific a
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning ACRS.
